Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Omicron Variant of Covid-19: A Focused Review of Biologic, Clinical, and Epidemiological Changes Publisher



Majlesi H1 ; Shahsavan S1 ; Farsi Y1 ; Tamimi A1 ; Ilkhani S2 ; Tajabadi Z3 ; Naserghandi A1 ; Fakour N4 ; Javad Nasiri M5 ; Nazemallhoseinimojarad E4 ; Safavinaini SAA4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  3. 3. Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Immunopathologia Persa Published:2023


Abstract

On 25 November 2021, the world health organization listed Omicron as a newly arisen and the fifth variant of concern (VoC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The genome sequence of Omicron showed the utmost number of mutations compared to other known VoCs up to now, and it was regarded as the only SARS-CoV-2 variant with changes in the receptor-binding domain (RBD). However, the Omicron is still detectable via previous polymerase chain reaction (PCR) tests. Clinical presentation of the disease is identical to previous VoCs, however in vitro and in vivo studies revealed a higher transmission rate. The biggest obstacles posed by Omicron are the immune escape and reduction in vaccine effectiveness, as indicated by many simulations and real-world studies. Although the efficacy of the two-dose vaccinations is suboptimal for Omicron, preliminary studies have considered the injection of a booster shot is beneficial and can decrease the risk of severe disease. All these new features of Omicron warranted close investigation of this VoC as a new chapter in the pandemic, especially with emersion of subvariants BA.4 and BA.5. This review presents a conspectus of the current knowledge on the COVID-19 Omicron variant biological, clinical, and epidemiological changes. © 2023 The Author(s).
Related Docs
1. Sars-Cov-2 Omicron (B.1.1.529) Variant: A Challenge With Covid-19, Diagnostics (2023)
2. Molecular Variants of Sars-Cov-2: Antigenic Properties and Current Vaccine Efficacy, Medical Microbiology and Immunology (2022)
3. Heterologous Immunization With Inactivated Vaccine Followed by Mrna-Booster Elicits Strong Immunity Against Sars-Cov-2 Omicron Variant, Nature Communications (2022)
4. Different Aspects in Explaining How Mutations Could Affect the Binding Mechanism of Receptor Binding Domain of Sars-Cov-2 Spike Protein in Interaction With Ace2, PLoS ONE (2023)
5. Sars-Cov-2 Omicron (B.1.1.529) Variant: No Time to Wait!, Acta Biomedica (2022)
Experts (# of related papers)
Nima Rezaei (2)
Seyed Rohollah Miri (1)